2 weeks Ago
Exelixis, Inc. ( NASDAQ: EXEL ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner - EVP & CFO Amy Peterson - EVP, Product Development, Medical Affairs & Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J.
Haley - EVP, Commercial Conference Call Participants Asthika Goonewardene - Truist Chi Fong - Bank of America Silvan Tuerkcan - Citizens JMP Michael Schmidt - Guggenheim Securities Gregory Renza - RBC Capital Markets Yaron Werber - TD Cowen Jay Olson - Oppenheimer Andy Hsieh - William Blair Ashwani Verma - UBS Peter Lawson - Barclays Lukas Shumway - BMO Capital Markets Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Joseph Catanzaro - Piper Sandler Operator Good day, ladies and gentlemen, and welcome to Exelixis Third Quarter 2024 Financial Results Conference Call. My name is Towanda, and I will be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Mr. Varant Shirvanian, Director of Investor Relations. Please proceed.
Varant Shirvanian Thank you, Towanda, and thank you all for joining us for the Exelixis third quarter 2024 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; and P.J.
Haley, our Executive Vice President of Commercial, who together will review our progress for the third quarter 2024 ended September 30, 2024. Amy Peterson, our Chief Medical Officer; and Dana Aftab, our Chief Scientific Officer are also on the call today and will participate in our question-and-answer session. During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles.
Please refer to today's.
